Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Summary

The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.

Timeline

Start

2010-02-22

Primary completion

2017-05-31

Completion

2018-12-17

Outcome

Outcome not reported

Stopped: “For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.”

Drugs

Indications